Thrombosis can occur at any phase of essential thrombocythemia with JAK2V617F mutation: A single institutional study in Japan [6]

Leukemia

Volumn 21, Issue 7, 2007, Pages 1570-1571

  Ohyashiki, K ^a   Ito, Y ^a   Hori, K ^b   Sato, K ^b   Makino, T ^b   Ohyashiki, J H ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b NovusGene Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEMOGLOBIN; JANUS KINASE 2; TICLOPIDINE;

ADULT; AGED; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE SEQUENCE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INCIDENCE; LETTER; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; THROMBOCYTE COUNT; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; WILD TYPE;

EID: 34250784502     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404666     Document Type: Letter

References (8)

1. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005; 366: 1945-1953.
2. V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 2007, doi:10.1038/sj.leu.2404604.
3. Harrison CN. Platelet and thrombosis in myeloproliferative diseases. Hematology 2005, American Society of Hematology, Education Program Book 2005, 409-415.
4. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847-1879.
5. V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208-213.
6. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2V617F mutation is associated with a higher hemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2005; 132: 244-250.
7. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2V617F mutation status. Haematologica 2007; 92: 135-136.
8. Carobbio A, Finazzi G, Guerini V, Spinelli O, Federica S, Delaini F et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors and Jak2 mutation status. Blood 2007; 109: 2310-2313.